BioScrip Value Stock - Dividend - Research Selection
Market price: 13,33 USD
BioScrip Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||39.467.000|
|Free cash flow||11.175.000|
|Liabilities & Shareholders equity||2.589.550.000|
|Diluted shares outstanding||38.734.800|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||516.334.880,00 USD|
|Raw Data Source||US GAAP in Millionen USD|
Description of the company
BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient\'s homes, outpatient clinics, nursing facilities, physician\'s offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.